The COVID-19 pandemic has changed the way we live and work. The way out is the vaccine — or, as turns out, several vaccines, developed by many organizations. They’re now making it into the arms of people around the world, and their supply-chain journey serves as an interesting use case for examining security threats.
In the era of “fake news,” the pandemic took the world by surprise. Humanity went through the inevitable stages of grieving, the first of which was denial. News didn’t immediately filter out of official channels. Concern escalated with reporting of the first cases in each part of the world. Healthcare professionals scrambled, and official reporting was slow at first. Drawing on reports from schools, local news, workplaces and social media, some organizations were better prepared than others. As early as January of 2020, it was clear that the entire world was about to go into crisis mode. Some businesses cut down on travel, started planning for remote work, or ordered supplies that would soon run short.
Since then, all eyes have been on vaccine development — whether and when it would become available. At the same time, manufacturers and distributors faced any number of threats to the security of their product. Nghi Luu, supply-chain risk leader at Cisco, summed it up: “We’ve come to realize that it’s not just about boxes getting from Point A to Point B. It’s geopolitical risks, cyber risks, overall supply-chain continuity risks.” This could mean changing legal environments, customs restrictions, political sanctions, logistical delays, infrastructure constraints, or labor actions. Only by employing proactive intelligence will we be able to shift the vaccine supply-chain security posture from reactive to proactive.
Read the Full Article in SupplyChainBrain to learn more about supply-chain risks related to the COVID-19 vaccine.